Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zmax Clear all

Conditions: Mycobacterium Avium Complex Lung Disease
Interventions: Azithromycin; Drug
Lead sponsor: The University of Texas Health Science Center at Tyler; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2017
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, Standard of Care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Dry Eye Disease
Interventions: Azithromycin Ophthalmic Solution, 1%, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Artesia, California • Newport Beach, California • Petaluma, California + 6 more

Conditions: Preterm Prelabor Rupture of Membranes, PPROM
Interventions: Azithromycin (Azithro), Standard Azithromycin Dosing; Drug
Lead sponsor: Alexa Henderson; Other
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Uncomplicated Urogenital Gonorrhea
Interventions: solithromycin, ceftriaxone, azithromycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio

Conditions: Infection, Obstetric Labor Complications, Endometritis, Cesarean Delivery Affecting Fetus, Wounds Injuries
Interventions: Vaginal Preparation; Procedure
Lead sponsor: Womack Army Medical Center; Federal
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Bragg, North Carolina

Conditions: Infectious Disease, Drug Effect, Clinical Infection
Interventions: Azithromycin Oleogel (Oral and Rectal); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: azithromycin 250 mg tablets, placebo tablets; Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 6 Years to 18 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 31
States / cities: Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more

Conditions: Tonsillitis
Interventions: amoxicillin, azithromycin SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 33
States / cities: Hoover, Alabama • Pelham, Alabama • Fresno, California + 20 more

Conditions: Bacterial Conjunctivitis
Interventions: AzaSite, Tobramycin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Littleton, Colorado • Atlantis, Florida + 23 more

Conditions: COVID-19, SARS-CoV 2
Interventions: Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 7 more

Conditions: Gonorrhoea
Interventions: Cefixime; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: SARS-CoV-2
Interventions: Standard of care, Hydroxychloroquine, Azithromycin; Other · Drug
Lead sponsor: Duke University; Other
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Community-Acquired Pneumonia (CAP)
Interventions: IV azithromycin, ceftriaxone, oral azithromycin, IV levofloxacin, oral levofloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 22
States / cities: Birmingham, Alabama • Long Beach, California • Sylmar, California + 18 more

Conditions: Sickle Cell Disease
Interventions: Azithromycin, Placebo; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: COVID, COVID-19, Corona Virus Infection, Coronavirus Infection, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Coronavirus-19, SARS-CoV 2, SARS Pneumonia
Interventions: hydroxychloroquine, Azithromycin, Ritonavir, Lopinavir; Drug
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ventura, California

Conditions: Malaria
Interventions: Fixed combination of Azithromycin and Chloroquine, Azithromycin and Chloroquine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gonorrhea
Interventions: Gepotidacin, Ceftriaxone, Azithromycin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bacterial Infections, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Asthma
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Peoria, Illinois • Kansas City, Kansas • Cleveland, Ohio + 2 more

Conditions: Pregnancy Preterm, Pregnancy Prom, PROM, Preterm (Pregnancy), PROM (Pregnancy), Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/Labor, Premature Birth
Interventions: Azithromycin Pill, Amoxicillin Pill; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Azithromycin, Zithromax®; Other · Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Search by objective public record fields.

Azithromycin in the Treatment of M. Avium Complex Lung Disease

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

Extended Azithromycin Treatment in Prelabor Rupture of Membranes

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections

A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of Azithromycin SR Versus Amoxicillin For The Treatment Of Strep Throat In Children

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study

Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia

Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

Azithromycin 600 Mg Tablets, Fasting

A Study of Combination Therapies to Treat COVID-19 Infection

A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)

A Study of Azithromycin in HIV-Infected Patients

AZMATICS: AZithroMycin/Asthma Trial In Community Settings

Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions